UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934


 

For the month of March 2023

 

Commission File Number: 001-40858

 

XORTX Therapeutics Inc.

3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    XORTX THERAPEUTICS INC.  
    (Registrant)  
         
Date: March 31, 2023 By: /s/ Allen Davidoff  
    Name: Allen Davidoff  
    Title:

Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EXHIBIT INDEX

 

99.1 Consolidated Financial Statements for the year ended December 31, 2022, 2021 and 2020
99.2 Management Discussion and Analysis for the year ended December 31, 2022
99.3 Annual Information Form for the year ended December 31, 2022
99.4 CEO Certificate
99.5 CFO Certificate